1,721,033 research outputs found
TOLERABILITYAND QUALITY OF LIFE IN ELDERLY PATIENTS TREATEDWITH BEVACIZUMAB FOR METASTATIC COLORECTAL CANCER
No full textmonoclonal
antibody, in combination with regimens based on 5FU/LV (or
capecitabine) ± irinotecan or oxaliplatin, considerably improved
prognosis of patients with metastatic colorectal cancer (mCRC).
However, potential adverse events such as hypertension, proteinuria,
bleeding, gastrointestinal perforation and thrombosis should
be considered especially in elderly patients. Aim of our study was
to assess bevacizumab-related adverse events and their influence
on quality of life in two groups of patients with mCRC.
Patients and methods. From January 2008 to June 2010 we
studied 59 patients with mCRC, receiving first-line chemotherapy
plus bevacizumab (5 mg/kg every 2 weeks), divided in two
groups, the first of 28 patients aged ≤70 years (range 35-70;
mean 58.4 years) and the second of 31 patients >70 years (range
71-79; mean 72.7 years). Patients with impaired renal function
and/or proteinuria ≥0.5 g/day were excluded. Adverse events
were defined according to the National Cancer Institute Common
Terminology Criteria (NCI-CTCAE v3.0.) Quality of life was assessed
with FACT-C, EORTC-C30 and CR38 questionnaires. Patients
were evaluated at baseline, at each cycle of therapy, three
and six months after the end of chemotherapy.
Results. Any grade hypertension occurred in 7 (25%) patients
≤70 years and in 9 (29%) older patients. Grade 3 hypertension,
requiring the initiation or a change of antihypertensive therapy,
was observed in 3 (10.7%) patients ≤70 years and in 4 (12.9%)
patients >70 years. Proteinuria occurred in 8 (28.6%) patients
≤70 years and in 9 (29%) older patients. Grade 4 hypertension
(hypertensive crisis) and/or grade 4 proteinuria (nephrotic syndrome)
was not seen. The FACT-C and EORTC questionnaires
showed that bevacizumab-related side effects had no impact on
quality of life.
Conclusion. In our study combination therapy with bevacizumab
was well tolerated with a generally manageable safety
profile in all patients. Bevacizumab-related adverse events such
as hypertension and proteinuria, while noting more prevalent in
patients aged >70 years, had no significant effects on quality of life
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
TOLLERABILITA' DEL BEVACIZUMAB IN PAZIENTI ANZIANE CON CANCRO DELLA MAMMELLA METASTATICO"TRIPLE NEGATIVE"
No full textCARDIOTOSSICITà IN PAZIENTI ANZIANE CON CANCRO DELLA MAMMELLA IN TRATTAMENTO CON TRASTUZUMAB
No full textobjective. TRASTUZUMAB, A HUMANIZED MONOCLONAL ANTIBODY DIRECTED AGAINST HER2, IS INDICATED FOR PATIENTS WITH HER2 POSITIVE EARLY BREAST CANCER (EBC)OR METASTATIC BREAST CANCER (MBC). SEVERAL STUDIES SHOWED AN INCREASED RISK OF CARDIOTOXICITY IN PATIENTS TREATED WITH TRASTUZUMAB. THE AIM OF OUR STUDY WAS TO EVALUATE ANY CARDIAC EFFECTS IN PATIENTS TREATED WITH TRASTUZUMAB FOR EBC OR MBC.
methods.FROM JANUARY 2007 TO MARCH 2009, WE EVALUATED 27 PATIENTS (1570YEARS) WITH EBC IN ADJUVANT TREATMENT WITH TRASTUZUMAB , AFTER CHEMIOTHERAPY WITH ANTHRACYCLINES AND TAXANES, AND 24 PATIENTS(1370YEARS) WITH MBC IN TREATMENT WITH CHEMOTHERAPY AND TRASTUZUMAB. CARDIAC EVENTS WERE DWFINED AS ASYMPTOMATIC (LVEF>50% WITH DECREASE >10% RELATIVE TO BASELINE) OR SYMPTOMATIC (GRADE 3OR4 LEFT VENTRICULAR SYSTOLIC DYSFUNCTION)ACCORDING TO THE NATIONAL CANCER INSTITUTE COMMON TERMONILOGY CRITERIA FOR ADVERSE EVENTS (NCI-CTCAE V3.0.) CARDIAC FUNCTION WAS ASSESED EVERY 3 MONTHS BY ECHOCARDIOGRAM WITH LVEF.
results.IN EBC GROUP, 2 PATIENTS>70 YEARS AND 2 >70 YEARS PRESENTED AN ASYMPTOMATIC CARDIAC EVENT. IN MBC GROUP, 2 PATIENTS70 YEARS PRESENTED AN ASYMPTOMATIC CARDIAC EVENT. IN MBC GROUP, 2 PATIENTS 70YEARS PRESENTED AN ASYMPTOMATIC CARDIAC EVENTS. ONE PATIENT (AGED >70 YEARS) WITH METASTATIC DISEASE PRESENTED A GRADE 3 LEFT VENTRICULAR SYSTOLIC DYSFUNCTION.
conclusion. OUR STUDY SHOWS THAT CARDIAC EVENTS RELATED TO THE ADMINISTRATION OF TRASTUZUMAB ARE USUALLY ASYMPTOMATIC, CAUSE A REVERSIBLE DECREASE IN LVEF AND OCCUR MORE FREQUENTLY IN PATIENT AGED >70YEARS, WITH A LOWER LVEF PRIOR TO TREATMENT
Variations on the Author
Full text link“Variations on the Author” discusses two of Eduardo Coutinho’s recent films (Um Dia na Vida, from 2010, and Últimas Conversas, posthumously released in 2015) and their contribution to the general question of documentary authorship. The director’s filmography is characterized by a consistent yet self-effacing form of authorial self-inscription: Coutinho often features as an interviewer that rather than express opinions propels discourses; an interviewer that is good at listening. This mode of self-inscription characterizes him as an author who is not expressive but who is nonetheless markedly present on the screen. In Um Dia na Vida, however, Coutinho is completely absent form the image, while Últimas Conversas, on the contrary, includes a confessional prologue that moves the director from the margins to the center of his films. This article examines the ways in which these works stand out in the filmography of a director who offers new insights into the notion of cinematic authorship
Appropriate Similarity Measures for Author Cocitation Analysis
Full text linkWe provide a number of new insights into the methodological discussion about author cocitation analysis. We first argue that the use of the Pearson correlation for measuring the similarity between authors’ cocitation profiles is not very satisfactory. We then discuss what kind of similarity measures may be used as an alternative to the Pearson correlation. We consider three similarity measures in particular. One is the well-known cosine. The other two similarity measures have not been used before in the bibliometric literature. Finally, we show by means of an example that our findings have a high practical relevance.information science;Pearson correlation;cosine;similarity measure;author cocitation analysis
Dispelling the Myths Behind First-author Citation Counts
Full text linkWe conducted a full-scale evaluative citation analysis study of scholars in the XML research field to explore just how different from each other author rankings resulting from different citation counting methods actually are, and to demonstrate the capability of emerging data and tools on the Web in supporting more realistic citation counting methods. Our results contest some common arguments for the continued
use of first-author citation counts in the evaluation of scholars, such as high correlations between author rankings by first-author citation counts and other citation
counting methods, and high costs of using more realistic citation counting methods that are not well-supported by the ISI databases. It is argued that increasingly available digital full text research papers make it possible for citation analysis studies to go beyond what the ISI databases have directly supported and to employ more
sophisticated methods
koamabayili/VECTRON-author-checklist: VECTRON author checklist
No full textWe have done our best to complete the author checklist relating to the use of animals in the hut study. Note that the objective for the hut study was to evaluate the IRS treatment applications for residual efficacy against Anopheles mosquitoes, including the local An. coluzzii mosquito population. Cows were only used to attract mosquitoes into the huts and no tests were carried out directly on the cows. The author checklist is intended for use with studies where experiments are carried out on animals, which is why we have had such difficulty in completing this for the hut study, as many of the questions do not relate to how the cows were used
- …
